CAS NO: | 1216941-48-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Paritaprevir (ABT-450) is a potent, orally active and antiviralnon-structural protein 3/4A (NS3/4A) proteaseinhibitor with EC50s of 1 and 0.21 nM againstHCV1a and 1b, respectively. Paritaprevir is also aSARS-CoV3CLproinhibitor with an IC50of 1.31 μM. Paritaprevir is metabolized primarily bycytochrome P450(CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor)[1][2][3][4]. | ||||||||||||||||
IC50& Target | EC50: 1 nM (HCV 1a), 0.21 nM (HCV 1b)[1] | ||||||||||||||||
体外研究 (In Vitro) | Paritaprevir hasin vitroantiviral activity against HCV GT1-4 and GT6 (EC50range, 0.09 to 19 nM), with an EC50of 0.09 nM against GT4a[2]. | ||||||||||||||||
体内研究 (In Vivo) | The combination of Paritaprevir,Ritonavir,Ombitasvir(an NS5A protein inhibitor), andDasabuvir(an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections[1][4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 765.88 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C40H43N7O7S | ||||||||||||||||
CAS 号 | 1216941-48-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 125 mg/mL(163.21 mM) H2O : ≥ 0.1 mg/mL(0.13 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|